Nykode Therapeutics AS NYKD
Oslo Børs · Healthcare · Biotechnology
2.99 NOK
+1.0%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Nykode Therapeutics
| USD million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 7 | 13 | 9 | 0 |
| EBITDA | −49 | −42 | −43 | −16 |
| Net income | −43 | −35 | −39 | −12 |
| Balance sheet | ||||
| Equity | 157 | 171 | 136 | 92 |
| Total debt | 6 | 6 | 3 | 3 |
| Cash | 206 | 162 | 115 | 60 |
| Net debt | −200 | −156 | −111 | −57 |
| Ratios and per share | ||||
| EBITDA margin | −682.6% | −323.5% | −496.3% | – |
| Profit margin | −596.3% | −272.5% | −447.3% | – |
| Return on equity | −27.2% | −20.5% | −28.5% | −13.4% |
| Earnings/share (USD) | −0.15 | −0.11 | −0.12 | −0.04 |
| Book value/share (USD) | 0.53 | 0.52 | 0.42 | 0.28 |
| Shares outstanding (M) | 295 | 327 | 327 | 327 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | – |
| P/B | 1.1 |
| EV / EBITDA | – |
| Net debt / EBITDA | – |
| Return on equity | −13.4% |
| Profit margin | – |
| Beta 1Y | 0.85 |
| Revenue growth 1Y | −100.0% |
| ROE avg. 3Y | −20.8% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (NOK)
| 2025 | 1.00 |
Not investment advice. Figures may contain errors from the data source.